Table 1.
Characteristics of patients with liver cirrhosis.
| Variable | Total (n = 101) | Non-ACLF Group (n = 54) |
Pre-ACLF Group (n = 13) |
Post-ACLF Group (n = 34) |
|---|---|---|---|---|
| Age (years) | 71 (62–75) | 69 (63–75) | 73 (71–81) | 71 (62–77) |
| Sex (male/female) | 64/37 | 32/22 | 8/5 | 24/10 |
| Etiology (HBV/HCV/alcohol/NASH/AIH/PBC/others) | 5/23/40/14/7/5/7 | 2/14/18/11/3/4/2 | 1/5/5/1/0/1/0 | 2/4/17/2/4/0/5 |
| Albumin (g/dL) | 3.2 (2.8–3.9) | 3.8 (3.4–4.2) | 3.0 (2.9–3.2) * | 2.5 (2.1–3.0) *, ** |
| Aspartate aminotransferase (U/L) | 43 (32–76) | 36 (28–50) | 42 (39–69) | 80 (42–232) *, ** |
| Alanine aminotransferase (U/L) | 28 (19–58) | 24 (17–41) | 27 (23–39) | 65 (30–113) *, ** |
| Blood urea nitrogen (mg/dL) | 16 (13–25) | 15 (12–21) | 16 (14–20) | 22 (12–37) * |
| Creatinine (mg/dL) | 0.9 (0.7–1.2) | 0.8 (0.5–1.0) | 1.0 (0.9–1.1) * | 1.1 (0.7–1.7) * |
| Total bilirubin (mg/dL) | 1.6 (1.0–4.1) | 1.1 (0.9–1.6) | 1.8 (1.1–2.2) * | 7.1 (5.0–10.2) *, ** |
| Prothrombin time (%) | 61 (40–73) | 65 (55–73) | 67 (62–79) | 33 (28–40) *, ** |
| Platelet count (×104/mm3) | 9.2 (6.3–12.8) | 9.6 (7.5–12.8) | 6.8 (5.5–13.0) | 7.7 (6.0–11.8) * |
| C-reactive protein (mg/dL) | 0.3 (0.0–1.0) | 0.1 (0.0–0.3) | 0.2 (0.1–0.6) | 1.5 (0.9–4.3) *, ** |
| MELD score | 10 (9–17) | 9 (8–11) | 9 (7–12) | 20 (14–28) *, ** |
Data are expressed as median (interquartile range). HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; MELD, model for end-stage liver disease. * p < 0.05 between non-ACLF and pre-ACLF, or post-ACLF group. ** p < 0.05 between pre-ACLF and post-ACLF group.